Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Puro, Vincenzo ^a   Palummieri, Antonio ^a   De Carli, Gabriella ^a   Piselli, Pierluca ^a   Ippolito, Giuseppe ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antiretroviral drugs; Attitudes; Health knowledge; HIV healthcare providers; HIV pre exposure prophylaxis; HIV prevention; Practice

Indexed keywords

ADULT; ARTICLE; BEHAVIOR THERAPY; CONTROLLED STUDY; DRUG COST; DRUG INFORMATION; DRUG MONITORING; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE SURVEY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MALE; MEDICAL SPECIALIST; PATIENT ADVOCACY; PATIENT COUNSELING; PERSONAL EXPERIENCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; QUESTIONNAIRE; SELF REPORT;

ADULT; ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG PRESCRIPTIONS; FEMALE; FOCUS GROUPS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 84877600920     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-217     Document Type: Article

References (35)

1. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, Katabira E, Bertozzi SM, Schwartländer B, Cohen MS. HIV prevention transformed: the new prevention research agenda. Lancet 2011, 378:269-278. 10.1016/S0140-6736(11)60877-5, 3606928, 21763938.
2. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011, 52:793-800. 10.1093/cid/ciq243, 3106261, 21367734.
3. Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA, . HIV Research Network Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr 2012, 60:249-259. 10.1097/QAI.0b013e318258c696, 22531758, HIV Research Network.
4. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, . CAPRISA 004 Trial Group Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174. 10.1126/science.1193748, 3001187, 20643915, CAPRISA 004 Trial Group.
5. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV, . iPrEx Study Team Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599. 10.1056/NEJMoa1011205, 3079639, 21091279, iPrEx Study Team.
6. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, . Partners PrEP Study Team Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012, 367:399-410. 10.1056/NEJMoa1108524, 22784037, Partners PrEP Study Team.
7. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, . TDF2 Study Group Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012, 367:423-434. 10.1056/NEJMoa1110711, 22784038, TDF2 Study Group.
8. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, . FEM-PrEP Study Group Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012, 367:411-422. 10.1056/NEJMoa1202614, 22784040, FEM-PrEP Study Group.
9. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012, 26:F13-F19. 10.1097/QAD.0b013e3283522272, 22333749.
10. National Institute of Allergy and Infectious Diseases (NIAID) NIH modifies 'VOICE' HIV prevention study in women National Institutes of Health, http://www.nih.gov/news/health/sep2011/niaid-28.htm, National Institute of Allergy and Infectious Diseases (NIAID).
11. Ministry of Health Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. Luglio 2012, [http://www.salute.gov.it/imgs/C_17_pubblicazioni_1793_allegato.pdf], Ministry of Health.
12. Puro V, De Carli G, Schifano E, Piselli P, Orchi N, Pittalis S, Scognamiglio P, Cimaglia C, Agresta A, Ippolito G, . Italian Registry of Antireroviral PEP HIV post-exposure prophylaxis in Italy (1996-2009) [abstract]. Infection 2011, Suppl 1:S15-S16. Italian Registry of Antireroviral PEP.
13. Tripathi A, Ogbuanu C, Monger M, Gibson JJ, Duffus WA. Preexposure prophylaxis for HIV infection: healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J 2012, 105:199-206. 10.1097/SMJ.0b013e31824f1a1b, 22475669.
14. O'Brien K. Using focus groups to develop health surveys: an example from research on social relationships and AIDS-preventive behavior. Health Educ Behav 1993, 20:361-372.
15. White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDs 2012, 26:395-405.
16. Hosmer DW, Lemeshow S. Applied logistic regression 1989, New York, NY: Wiley.
17. Mammone A, Pezzotti P, Angeletti C, Orchi N, Carboni A, Navarra A, Sciarrone MR, Sias C, Puro V, Guasticchi G, Ippolito G, Borgia P, Girardi E, . SENDIH Study Group HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infect Dis 2012, 12:65. 10.1186/1471-2334-12-65, 3359282, 22433313, SENDIH Study Group.
18. Suligoi B, Boros S, Camoni L, Camoni L, Pugliese L. Aggiornamento delle nuove diagnosi di infezione da HIV al 31 dicembre 2009 e dei casi di AIDS in Italia al 31 dicembre 2010. Not Ist Super Sanità 2011, Suppl 1:3-27.
19. Suligoi B, Raimondo M, Fanales-Belasio E, Buttò S. The epidemic of HIV infection and AIDS, promotion of testing, and innovative strategies. Ann Ist Super Sanita 2010, 46:15-23.
20. Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, Steward WT, Morin SF. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One 2012, 7:e40603. 10.1371/journal.pone.0040603, 3394704, 22792384.
21. Schackman BR, Eggman AA. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr Opin HIV AIDS 2012, 7:587-592. 10.1097/COH.0b013e3283582c8b, 23076124.
22. Puro V, De Carli G, Piselli P, Sciarrone MR, Schifano E, Pittalis S, Ippolito G. HIV incidence among men who have sex with men prescribed postexposure prophylaxis. AIDS 2012, 26:1581-1583. 10.1097/QAD.0b013e328355375c, 22810374.
23. International Association of Physicians in AIDS Care Controlling the HIV epidemic with antiretrovirals: treatment as prevention and pre-exposure prophylaxis. IAPAC consensus statement 2012, [http://www.iapac.org/tasp_prep/assets/TPSlon12_consensus.pdf], International Association of Physicians in AIDS Care.
24. Centers for Disease Control and Prevention Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 2011, 60:65-68. Centers for Disease Control and Prevention.
25. McCormack S, Fidler S, Fisher M, British HIV, . Association, British Association for Sexual Health and HIV The British HIV association/British association for sexual health and HIV position statement on pre-exposure prophylaxis in the UK. Int J STD AIDS 2012, 23:1-4. 10.1258/ijsa.2011.051211, 22362679, Association, British Association for Sexual Health and HIV.
26. U.S. Food and Drug Administration FDA approves first drug for reducing the risk of sexually acquired HIV infection [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm], U.S. Food and Drug Administration.
27. World Health Organization Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV Recommendations for use in the context of demonstration projects 2012, [http://www.who.int/hiv/pub/guidance_prep/en/], World Health Organization.
28. Centers for Disease Control and Prevention Interim guidance for health-care providers electing to provide preexposure prophylaxis (PrEP) for the prevention of human immunodeficiency virus (HIV) infection in heterosexually active adults who are at ongoing, very high risk for sexual acquisition of HIV infection. MMWR 2012, 61:586-589. Centers for Disease Control and Prevention.
29. European Medicines Agency Reflection paper on the non-clinical and clinical development for oral and topical HIV pre-exposure prophylaxis (PrEP) [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/03/WC500124054.pdf], European Medicines Agency.
30. AIDS Vaccine Advocacy Coalition Ongoing PrEP trials [http://data.avac.org/OngoingPrEPTrials.aspx], AIDS Vaccine Advocacy Coalition.
31. Metzger DS, Koblin B, Turner C, Navaline H, Valenti F, Holte S, Gross M, Sheon A, Miller H, Cooley P, Seage GR. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET vaccine preparedness study protocol team. Am J Epidemiol 2000, 152:99-106. 10.1093/aje/152.2.99, 10909945.
32. Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, Mayer KH. Limited awareness and Low immediate uptake of Pre-exposure prophylaxis among Men Who have Sex with Men using an internet social networking site. PLoS One 2012, 7:e33119. 10.1371/journal.pone.0033119, 3314648, 22470438.
33. Mayer KH, Safren SA, Gordon CM. HIV care providers and prevention: opportunities and challenges. J Acquir Immune Defic Syndr 2004, Suppl 2:S130-S132.
34. Lindley LL, Coleman JD, Gaddist BW, White J. Informing faith-based HIV/AIDS interventions: HIV-related knowledge and stigmatizing attitudes at Project F.A.I.T.H. churches in South Carolina. Public Health Rep 2010, Suppl 1:12-20.
35. Colbert JA. Clinical decisions. Preexposure prophylaxis for HIV prevention-polling results. N Engl J Med 2012, 367:e22. 10.1056/NEJMclde1211517, 23013053.